FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313014204> ?p ?o ?g. }

• W4313014204 abstract "<b>Introduction:</b> Mepolizumab is a targeted, humanized anti–IL-5 monoclonal antibody that prevents IL-5 from binding to its receptor on eosinophils, and selectively inhibits eosinophilic inflammation. It is approved for the treatment of severe eosinophilic asthma. <b>Aim:</b> To determine the 2-year clinical experience, effectiveness, and safety of mepolizumab treatment for patients with severe eosinophilic asthma, in Greece. <b>Methods:</b> This is a prospective, multicenter, observational study. It was conducted in 22 different centers in Greece. The primary endpoint was to assess clinically significant asthma exacerbations (CSE) after 12 and 24months of treatment respectively. <b>Results:</b> 169 patients were eligible (28% male, mean±SD age 57.7±12.6). 134 (79%) completed the 24month follow-up. After 2years there was 72% reduction (p<0.001) of CSE, significant improvement in the ACT score from 15.2±4.5 to 21.8±3.1, and lung function as assessed by the increase in FEV1, from 1.87±0.7 to 2.2±0.8 L, p<0.001. OCS maintenance was significantly reduced from 10.6±7.5mg/day to 1.7±3mg/day, p<0.001 at 24months. 71% of those treated with OCS at baseline discontinued OCS altogether. At 24months, according to the pre-defined Response Definition 1, 83.8% of patients were responders and 19.6% were super-responders, and according to the Response Definition 2, 93% were responders and 27.5% were super-responders. No significant safety issues were observed. <b>Conclusions:</b> Mepolizumab was associated with significant reductions in the annual rate of exacerbations and maintenance OCS use, improvement in asthma control and lung function that were maintained after 2years of treatment." @default.
• W4313014204 created "2023-01-05" @default.
• W4313014204 creator A5000039499 @default.
• W4313014204 creator A5000598641 @default.
• W4313014204 creator A5005726251 @default.
• W4313014204 creator A5008518869 @default.
• W4313014204 creator A5010301737 @default.
• W4313014204 creator A5012594364 @default.
• W4313014204 creator A5019700943 @default.
• W4313014204 creator A5028687622 @default.
• W4313014204 creator A5030590637 @default.
• W4313014204 creator A5034624483 @default.
• W4313014204 creator A5035499507 @default.
• W4313014204 creator A5035756099 @default.
• W4313014204 creator A5037878781 @default.
• W4313014204 creator A5044334058 @default.
• W4313014204 creator A5045659067 @default.
• W4313014204 creator A5048314977 @default.
• W4313014204 creator A5049159982 @default.
• W4313014204 creator A5052634394 @default.
• W4313014204 creator A5054808253 @default.
• W4313014204 creator A5057520308 @default.
• W4313014204 creator A5058453327 @default.
• W4313014204 creator A5058794896 @default.
• W4313014204 creator A5065463544 @default.
• W4313014204 creator A5066749221 @default.
• W4313014204 creator A5067099675 @default.
• W4313014204 creator A5068337789 @default.
• W4313014204 creator A5072607244 @default.
• W4313014204 creator A5078371112 @default.
• W4313014204 creator A5079362853 @default.
• W4313014204 creator A5079746661 @default.
• W4313014204 creator A5081740713 @default.
• W4313014204 creator A5082116176 @default.
• W4313014204 creator A5084400561 @default.
• W4313014204 creator A5087458888 @default.
• W4313014204 date "2022-09-04" @default.
• W4313014204 modified "2023-09-27" @default.
• W4313014204 title "RELIght: A two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: evaluating the multiple components of response" @default.
• W4313014204 doi "https://doi.org/10.1183/13993003.congress-2022.468" @default.
• W4313014204 hasPublicationYear "2022" @default.
• W4313014204 type Work @default.
• W4313014204 citedByCount "1" @default.
• W4313014204 countsByYear W43130142042023 @default.
• W4313014204 crossrefType "proceedings-article" @default.
• W4313014204 hasAuthorship W4313014204A5000039499 @default.
• W4313014204 hasAuthorship W4313014204A5000598641 @default.
• W4313014204 hasAuthorship W4313014204A5005726251 @default.
• W4313014204 hasAuthorship W4313014204A5008518869 @default.
• W4313014204 hasAuthorship W4313014204A5010301737 @default.
• W4313014204 hasAuthorship W4313014204A5012594364 @default.
• W4313014204 hasAuthorship W4313014204A5019700943 @default.
• W4313014204 hasAuthorship W4313014204A5028687622 @default.
• W4313014204 hasAuthorship W4313014204A5030590637 @default.
• W4313014204 hasAuthorship W4313014204A5034624483 @default.
• W4313014204 hasAuthorship W4313014204A5035499507 @default.
• W4313014204 hasAuthorship W4313014204A5035756099 @default.
• W4313014204 hasAuthorship W4313014204A5037878781 @default.
• W4313014204 hasAuthorship W4313014204A5044334058 @default.
• W4313014204 hasAuthorship W4313014204A5045659067 @default.
• W4313014204 hasAuthorship W4313014204A5048314977 @default.
• W4313014204 hasAuthorship W4313014204A5049159982 @default.
• W4313014204 hasAuthorship W4313014204A5052634394 @default.
• W4313014204 hasAuthorship W4313014204A5054808253 @default.
• W4313014204 hasAuthorship W4313014204A5057520308 @default.
• W4313014204 hasAuthorship W4313014204A5058453327 @default.
• W4313014204 hasAuthorship W4313014204A5058794896 @default.
• W4313014204 hasAuthorship W4313014204A5065463544 @default.
• W4313014204 hasAuthorship W4313014204A5066749221 @default.
• W4313014204 hasAuthorship W4313014204A5067099675 @default.
• W4313014204 hasAuthorship W4313014204A5068337789 @default.
• W4313014204 hasAuthorship W4313014204A5072607244 @default.
• W4313014204 hasAuthorship W4313014204A5078371112 @default.
• W4313014204 hasAuthorship W4313014204A5079362853 @default.
• W4313014204 hasAuthorship W4313014204A5079746661 @default.
• W4313014204 hasAuthorship W4313014204A5081740713 @default.
• W4313014204 hasAuthorship W4313014204A5082116176 @default.
• W4313014204 hasAuthorship W4313014204A5084400561 @default.
• W4313014204 hasAuthorship W4313014204A5087458888 @default.
• W4313014204 hasConcept C126322002 @default.
• W4313014204 hasConcept C141105273 @default.
• W4313014204 hasConcept C142724271 @default.
• W4313014204 hasConcept C159654299 @default.
• W4313014204 hasConcept C181901479 @default.
• W4313014204 hasConcept C203014093 @default.
• W4313014204 hasConcept C2776042228 @default.
• W4313014204 hasConcept C2777037409 @default.
• W4313014204 hasConcept C2777832160 @default.
• W4313014204 hasConcept C2778564945 @default.
• W4313014204 hasConcept C2778690821 @default.
• W4313014204 hasConcept C2779758542 @default.
• W4313014204 hasConcept C71924100 @default.
• W4313014204 hasConcept C74172505 @default.
• W4313014204 hasConcept C90924648 @default.
• W4313014204 hasConceptScore W4313014204C126322002 @default.
• W4313014204 hasConceptScore W4313014204C141105273 @default.
• W4313014204 hasConceptScore W4313014204C142724271 @default.
• W4313014204 hasConceptScore W4313014204C159654299 @default.
• W4313014204 hasConceptScore W4313014204C181901479 @default.
• W4313014204 hasConceptScore W4313014204C203014093 @default.

• next